Ann M. Hanly - Feb 22, 2023 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Signature
/s/ Howard Horn, Attorney-in-Fact
Stock symbol
VIR
Transactions as of
Feb 22, 2023
Transactions value $
-$59,790
Form type
4
Date filed
2/24/2023, 07:35 PM
Previous filing
Mar 31, 2022
Next filing
Mar 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +37.5K +45.73% $0.00 120K Feb 22, 2023 Direct F1, F2
transaction VIR Common Stock Sale -$59.8K -2.3K -1.93% $25.97 117K Feb 23, 2023 Direct F3
holding VIR Common Stock 11.5 Feb 22, 2023 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +55K $0.00 55K Feb 22, 2023 Common Stock 55K $27.01 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2 Includes 532 shares of common stock acquired by the reporting person on May 31, 2022 pursuant to an employee stock purchase program.
F3 Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
F4 The shares are beneficially owned by the reporting person's spouse, for the benefit of a minor child.
F5 25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter.